Barrett esophagus screening: who is offered it, the tests, and what results mean
In the United States, no professional organization recommends esophageal cancer screening for people at average risk. (ACS, 2025) For people with long-term reflux and other risk factors, ACG suggests a single screening endoscopy to look for Barrett esophagus. (ACG, 2022)
What Barrett esophagus is
Barrett esophagus is a disorder in which the lining of the esophagus is damaged by stomach acid, leading to changes in the cells of the lining. People with Barrett esophagus have an increased risk of cancer in the area involved, but cancer is not common. Barrett esophagus itself does not cause symptoms, and many people with it have no symptoms. (MedlinePlus, Barrett esophagus) Changes of Barrett esophagus are found in about 10% of people who have GERD, and a risk of 0.5% per year for developing adenocarcinoma is thought to be a reasonable estimate. (NCI PDQ, 2025)
Who may be offered screening
- ACG (2022): a single screening endoscopy for people with chronic GERD symptoms and 3 or more additional risk factors: male sex, age over 50, White race, tobacco smoking, obesity, and a family history of Barrett esophagus or esophageal adenocarcinoma in a first-degree relative. (ACG, 2022)
- AGA (2022): screening with upper endoscopy may be considered for people with at least 3 established risk factors: male, non-Hispanic White, age over 50, a history of smoking, chronic GERD, obesity, or a family history of Barrett esophagus or esophageal adenocarcinoma. (AGA, 2022)
- After a negative screen: ACG suggests against repeat screening in people whose first screening endoscopy was negative. (ACG, 2022)
The tests
- Upper endoscopy with biopsies: the doctor looks at the inside of the esophagus through a flexible lighted tube called an endoscope and may remove small tissue samples to check for dysplasia (precancer cells) or cancer cells. (ACS, 2025) ACG suggests at least 8 biopsies when the screening endoscopy shows findings consistent with possible Barrett esophagus. (ACG, 2022)
- Swallowed capsule devices: some doctors may use a pill-shaped capsule device that you swallow. (NIDDK) These devices are swallowed and then withdrawn by mouth, collecting cell samples from the esophagus that are tested for markers linked to Barrett esophagus. ACG suggests a capsule sponge device combined with a biomarker is an acceptable alternative to endoscopy for screening. (ACG, 2022) It is not widely available. (MedlinePlus, Barrett esophagus)
- Harms: endoscopy has uncommon but serious side effects, which may include perforation, cardiopulmonary events and aspiration, and bleeding requiring hospitalization. People found to have Barrett esophagus may consider themselves ill even though their risk of cancer is low. (NCI PDQ, 2025)
What results mean and the follow-up intervals stated
ACG suggests a diagnosis of Barrett esophagus requires intestinal metaplasia in the tubular esophagus and columnar lining at least 1 cm long. It recommends that dysplasia of any grade be confirmed by a second pathologist with expertise in GI pathology, and that the length of the Barrett segment be considered when setting surveillance intervals. (ACG, 2022)
| Finding | ACG 2022 | NICE NG231 |
|---|---|---|
| No Barrett esophagus on a first screening endoscopy | ACG suggests against repeat screening. (ACG, 2022) | Not covered (NG231 is about people already diagnosed). (NICE NG231) |
| Barrett without dysplasia, shorter than 3 cm | Endoscopy every 5 years. (ACG, 2022) | Every 3 to 5 years if intestinal metaplasia is present; no surveillance if there is no intestinal metaplasia, once confirmed at 2 endoscopies. (NICE NG231) |
| Barrett without dysplasia, 3 cm or longer | Endoscopy every 3 years. (ACG, 2022) | Every 2 to 3 years. (NICE NG231) |
| Indefinite for dysplasia (confirmed by a second pathologist) | Repeat endoscopy within 6 months; if it again shows indefinite for dysplasia, endoscopy every year. (ACG, 2022) | Consider surveillance every 6 months. (NICE NG231) |
| Low-grade dysplasia (confirmed by a second pathologist), if surveillance is chosen | Endoscopy at 6 months and 12 months after diagnosis, then every year. (ACG, 2022) | Covered under treatment, which this page does not discuss. (NICE NG231) |
- High-grade dysplasia or early cancer: ACG and NICE advise endoscopic treatment rather than routine surveillance. This page does not cover treatment. (ACG, 2022)(NICE NG231)
- Stopping surveillance: ACG says discussion of stopping surveillance is merited when most people reach age 75, if it has not happened before, and that stopping is reasonable for people with an estimated survival of less than 5 years or who are no longer fit for repeated endoscopy. (ACG, 2022)
- Tailoring: NICE says to assess a person's cancer risk based on age, sex, family history of esophageal cancer and smoking history, and tailor surveillance within its intervals. (NICE NG231)
MedlinePlus, when to contact a medical professional. Contact your provider if: (MedlinePlus, Barrett esophagus)
- Heartburn lasts for longer than a few days, or you have pain or problems swallowing.
- You have been diagnosed with BE and your symptoms get worse.
- You develop new symptoms (such as weight loss, problems swallowing).
Where they differ:
- ACG (US, 2022): chronic GERD symptoms are required, plus 3 or more other risk factors, for a single screening endoscopy. (ACG, 2022)
- AGA (US, 2022): at least 3 risk factors, with chronic GERD counted as one of them, so screening may be considered without reflux symptoms. (AGA, 2022)
- NICE (UK, 2023): NG231 covers monitoring people already diagnosed, with shorter intervals than ACG for nondysplastic Barrett (every 2 to 3 years for 3 cm or longer, every 3 to 5 years for shorter segments with intestinal metaplasia). (NICE NG231)
- NCI (US): based on fair evidence, screening would result in no or minimal decrease in deaths from esophageal cancer in the U.S. population. (NCI PDQ, 2025)
- ACS (US): no screening for people at average risk; experts often recommend regular upper endoscopies for people with Barrett esophagus, and doctors are not certain how often the test should be repeated. (ACS, 2025)
- USPSTF (US): its topic list has no esophageal cancer or Barrett esophagus screening topic. (USPSTF topics)
Your doctor decides what your result means for you.
This page does not give treatment advice. If you have an abnormal result, see after an abnormal screening result for questions to ask.
Questions people ask
Who should be screened for Barrett esophagus?
ACG suggests a single screening endoscopy for people with chronic reflux (GERD) symptoms and 3 or more other risk factors: male sex, age over 50, White race, smoking, obesity, or a first-degree relative with Barrett esophagus or esophageal adenocarcinoma. AGA says screening may be considered with at least 3 risk factors, counting chronic GERD as one of them. (ACG, 2022) (AGA, 2022)
Is there screening for people at average risk?
No. In the United States, no professional organization recommends screening for esophageal cancer in people who are not at increased risk, because no screening test has been shown to lower the risk of dying from it at average risk. (ACS, 2025)
Is there a test without an endoscopy?
ACG suggests that a swallowable, nonendoscopic capsule sponge device combined with a biomarker is an acceptable alternative to endoscopy for screening. AGA says nonendoscopic cell-collection devices can be considered. MedlinePlus notes the swallowed capsule is not widely available. (ACG, 2022) (AGA, 2022) (MedlinePlus, Barrett esophagus)
How often is endoscopy repeated with Barrett esophagus?
It depends on the length of the Barrett segment and whether dysplasia is found. ACG suggests every 5 years for nondysplastic segments shorter than 3 cm and every 3 years for 3 cm or longer; NICE says every 3 to 5 years and every 2 to 3 years for the same groups. (ACG, 2022) (NICE NG231)
How likely is Barrett esophagus to turn into cancer?
NCI says a risk of 0.5% per year for developing adenocarcinoma is now thought to be a reasonable estimate. MedlinePlus says people with Barrett esophagus have an increased risk of cancer, but cancer is not common. (NCI PDQ, 2025) (MedlinePlus, Barrett esophagus)